Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01984073 · ClinicalTrials.gov registry record · Phase 1
Effects of Niacin On Fatty Acid Trapping
A Phase 1 study of Dyslipidemia, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT01984073 is a Phase 1 study of Dyslipidemia that has completed, run by University of Pennsylvania. The registered enrollment target is 26 participants, below the 362-participant average among 40 other Dyslipidemia trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01984073, a Phase 1 study of Dyslipidemia, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand whether a vitamin called NIcotinic ACid vitamIN (NIACIN for short, also known as vitamin B3) helps the body process dietary fat more efficiently. This is important because people with dyslipidemia have a problem with how they process fat, which raise the risk of heart disease.
Conditions Studied
Interventions
- DRUG ER Niacin Oral Fat Challenge
- DRUG IR Niacin Oral Fat Challenge
- OTHER Placebo Oral Fat Challenge
Study Locations (2)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Presbyterian Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-12 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01984073
The ClinicalTrials.gov registry entry for NCT01984073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 362-participant average among 40 other Dyslipidemia trials with a reported enrollment target (93% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 3 interventions - of which ER Niacin Oral Fat Challenge is the first listed.
NCT01984073 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01984073 about?
NCT01984073 is a clinical study titled "Effects of Niacin On Fatty Acid Trapping". The purpose of this study is to understand whether a vitamin called NIcotinic ACid vitamIN (NIACIN for short, also known as vitamin B3) helps the body process dietary fat more efficiently. This is important because people with dyslipidemia have a problem with how they process fat, which raise the ri...
What is the current status of trial NCT01984073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2012-12. Estimated completion is 2019-12.
What conditions does trial NCT01984073 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT01984073?
The interventions under investigation include: ER Niacin Oral Fat Challenge (DRUG), IR Niacin Oral Fat Challenge (DRUG), Placebo Oral Fat Challenge (OTHER).
Who is sponsoring clinical trial NCT01984073?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01984073 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
RECRUITING · Phase 1
-
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
COMPLETED · Phase 1
-
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
COMPLETED · Phase 1
-
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
COMPLETED · Phase 1
-
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
COMPLETED · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.